KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Change in Accured Expenses (2016 - 2025)

Gilead Sciences (GILD) has disclosed Change in Accured Expenses for 17 consecutive years, with -$395.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 229.51% year-over-year to -$395.0 million, compared with a TTM value of $6.0 million through Dec 2025, down 94.44%, and an annual FY2025 reading of $6.0 million, down 94.44% over the prior year.
  • Change in Accured Expenses was -$395.0 million for Q4 2025 at Gilead Sciences, down from $811.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.5 billion in Q4 2021 and bottomed at -$1.7 billion in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $24.3 million, with a median of $37.5 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses surged 1348.0% in 2022, then tumbled 229.51% in 2025.
  • Year by year, Change in Accured Expenses stood at $1.5 billion in 2021, then tumbled by 76.88% to $356.0 million in 2022, then dropped by 10.96% to $317.0 million in 2023, then decreased by 3.79% to $305.0 million in 2024, then crashed by 229.51% to -$395.0 million in 2025.
  • Business Quant data shows Change in Accured Expenses for GILD at -$395.0 million in Q4 2025, $811.0 million in Q3 2025, and -$166.0 million in Q2 2025.